论文部分内容阅读
目的研究红乌合剂联合化疗在晚期食管癌治疗中的疗效。方法选取47例晚期食管癌患者,分为治疗组(24例,红乌合剂联合化疗组)与对照组(23例,单纯化疗组),21 d为1个周期,2个周期后观察临床疗效。结果在近期疗效方面,治疗组有效率为50.0%,疾病控制率为87.5%;对照组有效率为30.4%,疾病控制率为60.9%。两组间有效率比较无统计学意义(P>0.05),两组疾病控制率比较差异显著(P<0.05)。生存质量评分方面,在躯体、情绪、总生存质量及疼痛方面,两组比较差异显著(P<0.05)。毒副反应方面,两组比较差异不显著(P>0.05)。结论红乌合剂联合化疗治疗晚期食管癌可提高化疗疗效、改善患者生存质量,且未增加毒副反应,安全可靠。
Objective To study the curative effect of Hongwu Mixture combined with chemotherapy in the treatment of advanced esophageal cancer. Methods Forty-seven patients with advanced esophageal cancer were enrolled and divided into treatment group (24 cases) and control group (23 cases, chemotherapy alone group), one cycle after 21 days. The clinical effect was observed after 2 cycles . Results In the short term, the effective rate of the treatment group was 50.0% and the disease control rate was 87.5%. The control group was 30.4% and the disease control rate was 60.9%. There was no significant difference in the effective rate between the two groups (P> 0.05). There was significant difference in disease control rate between the two groups (P <0.05). In terms of quality of life score, there was significant difference between the two groups in physical, emotional, total quality of life and pain (P <0.05). Toxic side effects, the two groups showed no significant difference (P> 0.05). Conclusions The combination of “Hongwu Mixture” and chemotherapy in the treatment of advanced esophageal cancer can improve the curative effect of chemotherapy, improve the quality of life of the patients, and has no increase in toxicity and safety.